1994
DOI: 10.1001/archderm.130.1.66
|View full text |Cite
|
Sign up to set email alerts
|

Thalidomide neuropathy incidence and clinico-electrophysiologic findings in 42 patients

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

3
30
1
4

Year Published

1998
1998
2010
2010

Publication Types

Select...
6
1

Relationship

0
7

Authors

Journals

citations
Cited by 71 publications
(38 citation statements)
references
References 0 publications
3
30
1
4
Order By: Relevance
“…23 All patients should be carefully monitored to detect development of sensory peripheral neuropathy early on.…”
Section: Discussionmentioning
confidence: 99%
“…23 All patients should be carefully monitored to detect development of sensory peripheral neuropathy early on.…”
Section: Discussionmentioning
confidence: 99%
“…Increased age is suggested as a predisposing factor 42 but was not observed in our study or the study by Basturi-Garin et al 20 Incomplete improvement of the neuropathy with termination of thalidomide treatment supports the view that TPN is a neuronopathy. 18,19,27,43 None of our subjects was disabled by residual neuropathy. Thalidomide can be successfully restarted or reduced without progression of TPN.…”
Section: Commentmentioning
confidence: 75%
“…[16][17][18][19]42,43 Motor findings and painful dysesthesias are described with prolonged use, which were likely prevented in our cohort by careful monitoring and rapid adjustment of thalidomide dosing with the onset of TPN. 17 The acute onset of symptoms and signs followed by stabilization or improvement of neuropathy with reduction in thalidomide dosage enabled distinction of TPN from AIDS neuropathy.…”
Section: Commentmentioning
confidence: 99%
See 1 more Smart Citation
“…In this regard, higher doses (100-400 mg/day) of thalidomide were associated with an increased adverse dropout rate. [6][7][8] Low-dose (50 mg/day) thalidomide in combination with prednisone is better tolerated, and it alleviates anemia in approximately a quarter of treated patients with MF. [9][10][11][12][13] However, as a single agent, the antianemia activity of thalidomide is limited and long-term use has been associated with neuropathy.…”
Section: Introductionmentioning
confidence: 99%